|
|
|
|
|
|
Sponsored by: |
National Heart, Lung, and Blood Institute (NHLBI) |
Information provided by: | National Heart, Lung, and Blood Institute (NHLBI) |
ClinicalTrials.gov Identifier: | NCT00000539 |
To evaluate, in asymptomatic and symptomatic participants with peripheral arterial disease, the feasibility of recruitment and adherence, efficacy and safety of HDL-C raising along with effective control of LDL-C levels, antioxidant therapy, antithrombotic therapy, and their combinations.
Condition | Intervention | Phase |
Arterial Occlusive Diseases Cardiovascular Diseases Heart Diseases Vascular Diseases Diabetes Mellitus |
Drug: niacin Drug: pravastatin Drug: beta-carotene Drug: vitamin E Behavioral: dietary supplements Drug: vitamin C Drug: warfarin |
Phase III |
MedlinePlus related topics: | Diabetes Dietary Supplements Heart Diseases Vascular Diseases |
Study Type: | Interventional |
Study Design: | Treatment, Randomized |
Study Start Date: | September 1992 |
Estimated Study Completion Date: | March 1999 |
Show Detailed Description |
Ages Eligible for Study: | 18 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Men and women with symptomatic or asymptomatic peripheral arterial disease.
Study ID Numbers: | 82 |
First Received: | October 27, 1999 |
Last Updated: | January 10, 2006 |
ClinicalTrials.gov Identifier: | NCT00000539 |
Health Authority: | United States: Federal Government |
|
|
|
|